Related Experiment Videos
Promising systemic therapy for renal cell carcinoma.
Matthew M Cooney1, Scot C Remick, Nicholas J Vogelzang
1Nevada Cancer Institute, University of Nevada School of Medicine, Las Vegas, NV 89135, USA.
Current Treatment Options in Oncology
|August 19, 2005
Summary
New immunotherapies show promise for advanced kidney cancer, offering hope beyond current treatments like interferon and interleukin-2 (IL-2). These novel agents target key pathways, potentially improving outcomes for this refractory disease.
Area of Science:
- Oncology
- Immunotherapy
- Pharmacology
Background:
- Advanced kidney cancer causes over 12,000 deaths annually in the US.
- Interferon and high-dose interleukin-2 (IL-2) are standard immunotherapies but have limitations.
- High-dose IL-2 offers cures for 10-15% but is rarely used due to toxicity and inpatient needs.
Purpose of the Study:
- To review novel therapeutic compounds for advanced kidney cancer.
- To discuss preclinical and early clinical development of new agents.
- To highlight the urgent need for improved treatments in this refractory cancer.
Main Methods:
- Review of preclinical data for novel compounds.
- Analysis of early-phase clinical trial results.
- Discussion of molecular targets and mechanisms of action.
Main Results:
- Novel compounds target pathways like vascular endothelial growth factor receptors and raf kinase.
- Other agents focus on angiogenesis inhibition and antimicrotubule activity.
- These new therapies are showing promise in clinical trials.
Conclusions:
- Current immunotherapies (interferon, IL-2) have significant limitations for advanced kidney cancer.
- Novel targeted therapies are under investigation and demonstrate potential.
- Further development of these agents is crucial for improving patient survival and treatment options.